Last updated: February 20, 2026
What does Patent AU2016283018 Cover?
Patent AU2016283018, filed by GlaxoSmithKline (GSK), claims a novel pharmaceutical compound and its uses. The primary focus is on a specific class of kinase inhibitors intended for treating inflammatory diseases, autoimmune conditions, and certain cancers. The patent also extends to methods of synthesis, pharmaceutical compositions, and use cases.
Key Aspects of the Patent
-
Claimed Compound: The patent claims a heterocyclic compound with particular structural features designed to inhibit specific kinases such as Janus kinase (JAK).
-
Uses: It covers the use of the compound for treating inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, and ulcerative colitis. It also claims treatment of certain cancers, particularly hematological malignancies.
-
Methods of Synthesis: The patent details synthetic routes to generate the claimed compounds, emphasizing high yield and purity.
-
Pharmaceutical Compositions: It claims formulations suitable for oral and injectable administration, emphasizing stability and bioavailability.
Detailed Scope of Claims
Independent Claims
-
Claim 1: Defines a heterocyclic compound with a specified structure, including particular substituents at defined positions, aimed at kinase inhibition.
-
Claim 2: Covers the compound's use in manufacturing a medicament for treating autoimmune disorders or cancers.
-
Claim 3: Encompasses pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier.
Dependent Claims
-
Specify various substitutions at specific positions on the heterocyclic core, including different alkyl, aryl, and heteroaryl groups.
-
Cover methods of administration, dosing regimens, and formulation specifics.
Patent Term and Claims Scope
- Filed on December 7, 2016, published on June 8, 2018.
- Patent protection extends until December 7, 2036, assuming maintenance fees are paid.
- Claims are broad within the heterocycle class but focus on particular substitutions to narrow scope and avoid prior art.
Patent Landscape Analysis
Patent Family and Priority
- The patent family includes applications in other jurisdictions, notably the US and Europe, emphasizing its strategic importance.
- Priority claims establish priority dating back to 2015, allowing for extended patent life and global coverage.
Competitor Patents and Overlap
- Comparable patents held by AbbVie (e.g., US patents on JAK inhibitors) cover similar kinase inhibitors.
- GSK's patent claims propose narrower chemical modifications, possibly serving as a patent fence around specific compounds.
Freedom to Operate (FTO) Considerations
- Existing patents in the kinase inhibitor space suggest a crowded landscape.
- GSK's claims focus on specific substitutions, which may avoid claims of broader prior art but require careful FTO analysis in each jurisdiction.
Patent Trends and Innovation Focus
- The landscape in kinase inhibitors for autoimmune diseases and cancers shows growth since 2010.
- Other patents focus on different chemical classes (e.g., pyrimidines, imidazoles), indicating GSK's strategy to carve a niche.
Patent Litigation and Licensing
- No publicly available litigation files targeting this patent as of early 2023.
- GSK's licensing agreements include collaborations with biotech firms focusing on kinase inhibitors.
Implications for R&D and Investment
- The patent consolidates GSK's position in targeted kinase therapies.
- Its narrow scope around specific substitutions could serve as a reference point for developing similar compounds or designing around the patent.
- The broad claims on uses provide potential for extending patent rights if new indications or delivery methods are developed.
Summary of Patent Landscape
| Patent Area |
Key Patent Holders |
Patent Scope |
Filing Dates |
Status |
Strategic Notes |
| Kinase inhibitors |
GSK, AbbVie, Merck |
Varies from broad class to narrow compounds |
2010-2016 |
Active |
Competitive, high R&D cost, potential for licensing or cross-licensing |
| Selection of specific kinase inhibitors |
GSK (AU2016283018) |
Heterocyclic compounds with defined substitutions |
2016 |
Valid until 2036 |
Focused niche with potential for extension based on new uses or formulations |
Key Takeaways
- The patent covers a specific class of kinase inhibitors with therapeutic applications in inflammatory diseases and cancers.
- Its claims are targets for competitors' research, requiring ongoing monitoring.
- The patent landscape is crowded; claims focus on particular chemical modifications to achieve novelty.
- Patent protection extends until 2036, with strategic importance in GSK’s portfolio.
- Broad use claims open avenues for future therapeutic development.
FAQs
1. Can competitors develop similar kinase inhibitors without infringing this patent?
Yes, by designing compounds outside the specific substitutions claimed. However, they must avoid the heterocyclic core and the particular modifications covered.
2. How does this patent compare to global kinase inhibitor patents?
It targets a specific heterocyclic structure with defined substitutions, distinguishing it from broader patents covering different chemical classes.
3. What are the key considerations for licensing this patent?
Compatibility with existing pipeline compounds, the scope of licensed use, and potential for patent extension through additional filings.
4. Does the patent cover formulations and delivery methods?
Yes, claims include pharmaceutical compositions and administration routes, providing comprehensive coverage.
5. Are there known legal disputes surrounding this patent?
No publicly recorded disputes as of early 2023. Monitoring ongoing patent litigation is recommended.
References
[1] Australian Patent AU2016283018. (2016). GlaxoSmithKline.
[2] U.S. Patent US9,884,590. (2019). (Related kinase inhibitor patent by GSK).
[3] European Patent EP3002503. (2018). Comparative patent landscape for kinase inhibitors.
[4] Patent landscape reports. (2022). Clarivate Analytics.
